GCP Inspections: Corrective Measures For Adverse Findings Should Be Tested, US FDA Says

Sponsors, CROs and study investigators who receive an FDA Form 483 following a good clinical practice inspection should acknowledge the agency’s observations, explain the corrective actions planned, and how efficacy of those measures will be assessed, CDER officials say.